Joint studies will evaluate one or more of Pfizer’s investigational NASH therapies in combination with Novartis’s FXR agonist for the treatment of the progressive liver disease
https://www.businesswire.com/news/home/20181028005011/en/Pfizer-Announces-Clinical-Development-Agreement-Novartis-Advan
Like this:
Like Loading...
Related
Steatosite
The creation of the NASH Data Commons will provide a unified data system that promotes sharing of genomic and clinical data, forming the basis for a comprehensive knowledge system that centralises, standardises and makes accessible data. These datasets will lead to a much deeper understanding of which therapies are most effective for individual patients. With each new dataset added e.g. additional ‘omics’ data, it will evolve into a smarter, more comprehensive knowledge system that will foster important discoveries in chronic liver disease and increase the success of treatments for patients.
View all posts by Steatosite
Published by